Furthermore, one would expect the targeting of CD11b/CD18 and CD11c/CD18 to be associated with a risk of infection due to the inhibition of normal monocytes [242], and this may become particularly important for patients receiving AML therapy with hematological toxicity [3]. The gene discussed is ITGB2; the disease is acute myeloid leukemia.